

1 **Regional 4D Cardiac Magnetic Resonance Strain Predicts Cardiomyopathy**
2 **Progression in Duchenne Muscular Dystrophy**

3
4 Conner C. Earl^{1,2}, BS; Alexa M. Jauregui^{1,2}, BS; Guang Lin³, PhD; Kan N. Hor⁴, MD;
5 Larry W. Markham⁵, MD; Jonathan H. Soslow⁶, MD; Craig J. Goergen^{1,2}, PhD

- 6
7 1. Weldon School of Biomedical Engineering, Purdue University, West Lafayette, IN
8 2. Indiana University School of Medicine, Indianapolis, IN
9 3. Department of Mathematics & School of Mechanical Engineering, Purdue
10 University, West Lafayette, IN
11 4. The Heart Center, Nationwide Children's Hospital, Ohio State University,
12 Columbus, OH, USA
13 5. Division of Pediatric Cardiology, Riley Children's Hospital at Indiana University
14 Health, Indiana University School of Medicine, Indianapolis, IN
15 6. Division of Pediatric Cardiology, Department of Pediatrics, Vanderbilt University
16 Medical Center

17 **Short Title:** Regional 4D CMR Strain Predicts Progression in DMD CMP

18

Corresponding Authors:

Craig J. Goergen, PhD, FAHA
206 S. Martin Jischke Drive
West Lafayette, IN 47907, USA
cgoergen@purdue.edu

Jonathan H. Soslow, MD, MSCI
2200 Children's Way 5th Floor,
Nashville, TN 37232, USA
jonathan.h.soslow@vumc.org

19

20

21

22

23

24

25

26

27

28

29

30 **Abstract:**

31 **Background:** Cardiomyopathy (CMP) is the leading cause of death in Duchenne
32 muscular dystrophy (DMD). Characterization of disease trajectory can be challenging,
33 especially in the early stage of CMP where onset and clinical progression may vary.
34 Traditional metrics from cardiovascular magnetic resonance (CMR) imaging such as
35 LVEF (left ventricular ejection fraction) and LGE (late gadolinium enhancement) are
36 often insufficient for assessing disease trajectory. We hypothesized that strain patterns
37 from a novel 4D (3D+time) CMR regional strain analysis method can be used to predict
38 the rate of DMD CMP progression.

39

40 **Methods:** We compiled 115 short-axis cine CMR image stacks for n=40 pediatric DMD
41 patients (13.6±4.2 years) imaged yearly for 3 consecutive visits and computed regional
42 strain metrics using custom-built feature tracking software. We measured regional strain
43 parameters by determining the relative change in the localized 4D endocardial surface
44 mesh using end diastole as the initial reference frame.

45

46 **Results:** We first separated patients into two cohorts based on their initial CMR:
47 LVEF≥55% (n=28, normal cohort) and LVEF<55% (n=12, abnormal cohort). Using
48 LVEF decrease measured two years following the initial scan, we further subclassified
49 these cohorts into slow ($\Delta\text{LVEF}\% \leq 5$) or fast ($\Delta\text{LVEF}\% > 5$) progression groups for both
50 the normal cohort (n=12, slow; n=15, fast) and the abnormal cohort (n=8, slow; n=4,
51 fast). There was no statistical difference between the slow and fast progression groups
52 in standard biomarkers such as LVEF, age, or LGE status. However, basal
53 circumferential strain (E_{cc}) late diastolic strain rate and basal surface area strain (E_a)
54 late diastolic strain rate magnitude were significantly decreased in fast progressors in
55 both normal and abnormal cohorts ($p < 0.01$, $p = 0.04$ and $p < 0.01$, $p = 0.02$, respectively).
56 Peak E_a and E_{cc} magnitudes were also decreased in fast progressors, though these
57 only reached statistical significance in the normal cohort ($p < 0.01$, $p = 0.24$ and $p < 0.01$,
58 $p = 0.18$, respectively).

59

60 **Conclusion:** Regional strain metrics from 4D CMR can be used to differentiate
61 between slow or fast CMP progression in a longitudinal DMD cohort. These results
62 demonstrate that 4D CMR strain is useful for early identification of CMP progression in
63 patients with DMD.

64

65 **Clinical Perspective:**

66 Cardiomyopathy is the number one cause of death in Duchenne muscular dystrophy,
67 but the onset and progression of the disease are variable and heterogeneous. In this
68 study, we used a novel 4D cardiovascular magnetic resonance regional strain analysis
69 method to evaluate 40 pediatric Duchenne patients over three consecutive annual visits.
70 From our analysis, we found that peak systolic strain and late diastolic strain rate were
71 early indicators of cardiomyopathy progression. This method offers promise for early
72 detection and monitoring, potentially improving patient outcomes through timely
73 intervention and management.

74

75 **Key Words:** Duchenne muscular dystrophy, cardiomyopathy, strain, gadolinium,
76 progression, Left ventricular function, Diastolic dysfunction.

77

78 **Introduction:**

79 Duchenne muscular dystrophy (DMD) is a devastating X-linked genetic disease
80 characterized by progressive muscle weakness, loss of mobility, and often a
81 dramatically shortened lifespan¹⁻³. Muscle weakness and loss of ambulation are
82 hallmark features of this disease, however, DMD-associated cardiomyopathy (CMP) is
83 the number one cause of death in this population^{4,5}. While there is no cure for DMD,
84 advancements in research and medical care have enhanced the quality of life and
85 extended the life expectancy of individuals affected by this condition^{4,6}.
86 Among the various developments in the management of DMD, cardiac magnetic
87 resonance imaging (CMR) has emerged as the gold standard tool for assessing cardiac
88 involvement and tracking the progression of this disease⁷⁻¹⁰. However, given the
89 inherent variability in the onset and clinical progression of DMD, characterizing the

90 trajectory of the disease, particularly in the early stages of CMP, presents a notable
91 challenge¹¹.

92
93 CMR-derived metrics most often used in disease assessment include left ventricular
94 ejection fraction (LVEF) and late gadolinium enhancement (LGE)⁷. LVEF is a well-
95 accepted indicator of overall systolic function, but a decrease in LVEF below clinically
96 normal levels often occurs only after substantial disease progression¹¹. LGE is an
97 indicator of early disease and correlates with physiologic fibrofatty replacement of heart
98 muscle tissue in DMD¹². However, LGE might also be considered a relatively late
99 finding as it can only be detected when a substantial portion of the myocardium has
100 been affected. Cardiac strain measures the relative deformation of the myocardium
101 throughout the cardiac cycle with end diastole assumed to be the reference state. Strain
102 has shown promise as an early indicator of disease,⁸ but is not currently used
103 extensively in clinical decision making.

104
105 We have recently developed novel methods for assessing regional strain using stacked
106 short-axis CMR images¹³. This innovative approach involves the utilization of a method
107 for quantifying 4D (3D+time) cardiovascular magnetic resonance (CMR) regional strain.
108 With this approach, we hypothesize DMD patient groups can be differentiated based on
109 their strain patterns to predict the rate of CMP progression, contributing to a deeper
110 understanding of the disease, paving the way for more targeted interventions, and
111 eventually improving patient outcomes.

112

113 **Methods:**

114 *Patient Population:*

115 In this study, we analyzed data from patients with a range of DMD-associated CMP
116 from an observational study approved by the Vanderbilt Institutional Review Board. All
117 participants adhered to approved protocols and provided their consent or assent. The
118 original study enrolled DMD CMP patients who had received a phenotypic diagnosis of
119 DMD, subsequently confirmed through genetic testing or muscle biopsy. As possible,
120 each patient in the study had three consecutive CMR scans each about 12 months

121 apart (12.3 ± 0.8 months; mean \pm SD). Our study excluded patients with diagnoses other
122 than DMD and those with inadequate assessment or non-diagnostic results for LGE.

123

124 *Patient Stratification:*

125 DMD patients presented with a range of CMP severity at the initial visit: 12 with reduced
126 LVEF of $<55\%$ (30% of total) and 26 with LGE (65% of total). We initially categorized
127 patient CMP into Stage A (LVEF $\geq 55\%$, no LGE; $n=14$), Stage B (LVEF $\geq 55\%$, with LGE;
128 $n=14$), Stage C ($40\% < \text{LVEF} < 55\%$, with LGE; $n=9$), or Stage D (LVEF $< 40\%$, with LGE;
129 $n=3$) based on the 2022 AHA's guideline for the management of heart failure¹⁴. We also
130 grouped patients based on initial visit LVEF and progression after two years. We chose
131 to group patients this way in an effort to model the natural history differences between
132 DMD patients with normal LVEF ($\geq 55\%$) vs. those with abnormal LVEF ($< 55\%$). The
133 patient groups were further categorized by decrease in LVEF two years following the
134 initial visit as follows: normal, slow progression: initial LVEF $\geq 55\%$, +2 years $\Delta \text{LVEF}\% \leq 5$
135 ($n=12$), normal, fast progression: initial LVEF $\geq 55\%$, +2 years $\Delta \text{LVEF}\% > 5$ ($n=15$),
136 abnormal, slow progression: initial LVEF $< 55\%$ +2 years $\Delta \text{LVEF}\% \leq 5$ ($n=8$), abnormal,
137 fast progression: initial LVEF $< 55\%$, +2 years $\Delta \text{LVEF}\% > 5$ ($n=4$). One patient was
138 excluded due to poor image quality.

139

140 *Image Acquisition:*

141 We obtained CMR images using a 1.5 Tesla scanner (Avanto or Avanto Fit, Siemens
142 Healthineers, Erlangen, Germany) as described previously^{13, 15}. Briefly, we acquired
143 balanced steady-state free precession (bSSFP) cine images in the 4-chamber, 3-
144 chamber, 2-chamber, and a short-axis stack. Typical imaging parameters were 6-8 mm
145 thickness, 20-25 images per cardiac cycle with 11-17 short axis cine slices per patient.
146 LGE imaging included single-shot phase-sensitive inversion recovery bSSFP imaging
147 with an inversion time of 300 ms and segmented inversion recovery turboFLASH
148 sequences with optimized inversion recovery to null myocardial signal.

149 All images were analyzed by an image analyst with over 5 years of experience and all
150 analyses were verified by a pediatric cardiologist with more than 10 years of experience.

151 Ventricular function and volumes were calculated using Medis QMass (MedisSuite 2.1,

152 Medis, Leiden, The Netherlands). The presence or absence of LGE was qualitatively
153 assessed and localized using the standard 17-segment model¹⁶.

154

155 *Strain Analysis:*

156 We performed 4D CMR strain analysis using a custom-built graphical user interface in
157 MATLAB (R2022b, Mathworks, Natick, Massachusetts, USA) as described
158 previously¹³. In short, we first compiled short-axis cine CMR DICOM images into a
159 volumetric data viewer that could reconstruct the axial, sagittal, and coronal planes of
160 the heart. For each 4D image, the user then identified a centerline along the longitudinal
161 axis of the left ventricle and tracked apical and basal movement along this axis.
162 Following this step, four equally spaced parallel short axis slices along this axis were
163 identified. For each slice, the user tracked the movement of the endocardial and
164 epicardial borders throughout the cardiac cycle in both the short axis and in one of three
165 planes perpendicular to the short axis that corresponded approximately to conventional
166 long-axis, two-chamber, and four-chamber views. This method amounts to tracking a
167 structured set of 48 points throughout the myocardium in addition to basal and apical
168 movement across a representative cardiac cycle. Following this step, we used spatial
169 and temporal spline interpolation to create a dynamic 3D deformable mesh representing
170 the left ventricle^{13, 17, 18}. We then used this mesh to derive the following components of
171 strain throughout the entire 3D mesh: circumferential strain (E_{cc}), longitudinal strain (E_{ll}),
172 radial strain (E_{rr}), and surface area strain (E_a) in a Lagrangian reference frame as
173 described previously¹³. From each strain component, we also derived regional average
174 strain rates by measuring the slope of the strain curve in systole, early diastole, and late
175 diastole, as described previously^{13, 19}.

176

177 *Statistical Analysis:*

178 We assessed the distribution for each metric using a Shapiro-Wilk test ($p < 0.05$). Non-
179 parametric statistics were used for data sets not following a normal distribution. When
180 comparing two groups, we used t-test or Mann-Whitney test for parametric and non-
181 parametric data respectively, and used the Holm-Sidak method for adjusting the p-value
182 for multiple comparisons. When comparing multiple groups, we used an ANOVA with

183 the Tukey-Kramer method for multiple comparisons for parametric data or the Kruskal-
 184 Wallis test and Dunn's multiple comparison test for non-parametric data. For comparing
 185 categorical variables (i.e. LGE presence) we used a Fisher Exact Test.

186

187 **Results:**

188 Over the study period, we included 115 CMR studies in our analysis from n=40 patients.
 189 We imaged all of these patients using gadolinium contrast. LVEF, LGE status,
 190 demographic and clinical parameters in addition to other imaging variables were
 191 collected as outlined below in Table 1.

192


193 **Table 1:** Clinical information obtained over three annual visits from patients with
 194 Duchenne muscular dystrophy-associated cardiomyopathy (DMD CMP).

	Visit 1 (n=40)	Visit 2 (n=38)	Visit 3 (n=36)
Age (years)	12.4 [10.5-16.6]	12.8 [11.5-17.0]	13.7 [12.5-17.0]
Height (cm)	146 [127-163]	152 [142-161]	152 [142-163]
Weight (kg)	47.2 [36.4-65.0]	53.6 [39.5-69.9]	58.5 [43.2-72.8]
BSA (m ²)	1.4 [1.2-1.7]	1.5 [1.3-1.8]	1.6 [1.3-1.8]
HR (BPM)	103 [92-116]	97 [89-105]	100 [89-111]
Systolic (mmHg)	115 [107-120]	117 [106-123]	115 [105-120]
Diastolic (mmHg)	66 [61-74]	68 [63-74]	69 [59-76]
LVEF (%)	59 [51-62]	57 [49-59]	55 [49-58]
LVEDVI (ml/m ²)	59 [54-70]	61 [52-68]	65 [57-71]
LVESVI (ml/m ²)	24 [20-34]	26 [22-33]	29 [25-34]
CO (L/min)	4.9 [4.0-5.8]	4.7 [4.1-5.3]	5.1 [4.0-6.0]
LVEF<55%, n(%)	12 (30)	16 (42)	18 (50)
+LGE, n(%)	26 (65)	29 (76)	34 (94)
Stage A, n(%)	14 (35)	9 (24)	2 (6)
Stage B, n(%)	14 (35)	13 (34)	16 (44)
Stage C, n(%)	9 (22.5)	14 (37)	16 (44)
Stage D, n(%)	3 (7.5)	2 (5)	2 (6)

BSA, body surface area; HR, heart rate; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end diastolic volume indexed to BSA; LVESVI, left ventricular end systolic volume indexed to BSA; LVCO, left ventricular cardiac output; LGE, late gadolinium enhancement.

Stage A, LVEF>55%, LGE(-); Stage B, LVEF>55%, LGE(+); Stage C, 40%<LVEF<55%, LGE(+); Stage D, LVEF<40%, LGE(+). Values reported as median [interquartile range] or as number of subjects (percentage of group)—n(%).

195




196

197 **Figure 1:** DMD CMP heart failure staging and cohort overview. A) Heart failure staging
 198 criteria. B) Stacked column chart depicting patient groups at visit 1 (initial visit), visit 2
 199 (+1 year), and visit 3 (+2 years). C) Sankey diagram depicting heart failure stages
 200 across visits.

201

202 *Late Gadolinium Enhancement:*

203 We measured the presence of LGE in each patient and found that the percentage of
 204 patients with LGE increased over time from 65% (n=26) at the initial visit to 76% (n=29)
 205 at +1 year and 94% (n=34) at +2 years. Additionally, the highest number of patients had
 206 findings of LGE in the basal and lateral segments of the heart with 81% (n=29) of
 207 patients having LGE in the basal inferolateral segment of the heart and 78% (n=28) in
 208 the basal anterolateral segment of the heart (Figure 2B).




210 **Figure 2:** LGE presence increases over time in DMD, particularly in the basal and
 211 lateral regions of the heart. A) 17-segment polar plot map. B) Intensity plot depicting the
 212 percentage of patients with LGE findings for visit 1 (V1; initial visit; n=40), visit 2 (V2; +1
 213 year; n=38), and visit 3 (V3; +2 years; n=36), with lighter shading depicting a higher
 214 percentage of LGE. C) 17-segment plot depicting the percentage of the patient cohort
 215 with LGE based on region, with lighter shading depicting a higher percentage of LGE.

216


217 *Strain Mapping and Progression:*

218 We calculated circumferential (E_{cc}), longitudinal (E_{ll}), radial (E_{rr}), and surface area strain
219 (E_a) from 3D+time CMR images for each patient at the initial, second, and third visit. We
220 plotted E_{cc} and E_{ll} using a Cartesian color map where the region of the heart is
221 displayed on the y-axis and relative time in the cardiac cycle is depicted on the x-axis
222 (Figure 3 A-D). We also plotted E_{rr} and E_a at peak systole using a polar plot (Figure 3 A-
223 D). For many patients, we found striking qualitative differences in strain maps between
224 visits indicating an overall decrease in strain magnitude over time (Figure 3).



225 **Figure 3:** Regional 4D CMR strain metrics change over time in an individual patient. A)
226 Graphical depiction of strain component calculation and graphical representation for
227 circumferential (E_{cc}), longitudinal (E_{ll}), radial (E_{rr}), and surface area strain (E_a). B,C,D)
228 Strain maps for an individual patient at the initial visit (B), 2nd visit: +1 year (C), and 3rd
229 visit: +2 years (D).

230
 231 Using the same strain mapping conventions, we also plotted composite group-averaged
 232 strain maps to evaluate averaged strain differences and patterns between groups with
 233 varying CMP severity (Figure 4). While there were no statistical difference between
 234 LVEF for Stage A ($61.6 \pm 3.1\%$; mean \pm SD; $n=14$) and Stage B ($61.5 \pm 5.2\%$; $n=14$;
 235 $p=0.93$), there were significant differences in global peak strain values between Stage A
 236 and Stage B. These differences included E_{ll} (-10.9 ± 1.5 , -8.6 ± 1.4 , $p=0.002$), E_{rr} (27 ± 9.5 ,
 237 18.2 ± 6.3 , $p=0.038$), and E_a (-31.9 ± 3.4 , -28 ± 3.9 , $p=0.037$). There were no significant
 238 differences in global peak strain between Stage B and Stage C, though differences
 239 approached significance for basal E_a peak strain (-25.2 ± 2.8 , -22.4 ± 1.8 , $p=0.057$). There
 240 were, however, significant differences in global peak strain between Stage C and Stage
 241 D for E_{cc} (-9.6 ± 1.7 , -5.9 ± 2.4 , $p=0.017$) and E_a (-24.9 ± 1.9 , -16.2 ± 5.5 , $p=0.004$).
 242 Additional regional peak differences are shown in Supplemental Table 1.
 243




244 **Figure 4:** Regional 4D CMR strain metrics can differentiate between heart failure
245 stages. A,B,C,D) Initial visit, group-averaged circumferential (E_{cc}), longitudinal (E_{ll}),
246 radial (E_{rr}), and surface area strain (E_a) maps for Stage A (LVEF \geq 55%, no LGE), B
247 (LVEF \geq 55%, with LGE), C (40%<LVEF<55%, with LGE), or D (LVEF<40%, with LGE).
248 E,F,G,H) Global peak systolic strain values comparing heart failure stages at the initial
249 visit for E_{cc} (E), E_{ll} (F), E_{rr} (G), and E_a (H). * p <0.05 adjusted for multiple comparisons.

250

251 *Strain Mapping and Progression*

252 We further examined strain differences based on the progression of CMP from the initial
253 visit as measured by the change in LVEF. As described in the methods, we grouped our
254 patients into normal (LVEF \geq 55%) and abnormal (LVEF<55%) groups and further into
255 slow (+2 years: Δ LVEF% \leq 5) or fast (+2 years: Δ LVEF% $>$ 5) progressors based on
256 individual decrease in LVEF (Figure 5A). We were particularly interested in
257 distinguishing progression differences between individuals with baseline normal function
258 and those with baseline abnormal function. We found that at the initial visit, traditional
259 functional metrics did not show statistical differences in the normal cohort between slow
260 and fast progression including LVEF (p >0.99), age (p >0.99), and LGE status (p =0.704;
261 Figure 5B,C). We saw similar trends in the abnormal cohort between slow and fast
262 progression groups for LVEF (p =0.70) and age (p >0.99; Figure 5B,C). We did, however,
263 note distinct qualitative differences in initial visit group-averaged strain maps between
264 each progression group (Figure 5D-G) as well as in strain maps from representative
265 individuals from each group (Supplemental Figures 1-4).




266

267 **Figure 5:** Standard metrics cannot differentiate between fast and slow progression;
 268 however, group-averaged strain maps reveal distinct qualitative differences between
 269 groups. A) Progression group descriptions for normal, slow progression (initial
 270 LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progression (initial LVEF \geq 55% +2 years
 271 Δ LVEF% $>$ 5), abnormal, slow progression (initial LVEF $<$ 55% +2 years Δ LVEF% \leq 5), and
 272 abnormal, fast progression (initial LVEF $<$ 55% +2 years Δ LVEF% $>$ 5). B,C) LVEF
 273 comparison (B) and age comparison (C) at the initial visit between groups. D,E,F,G)
 274 Group averaged strain plots at the initial visit. * $p<0.05$ adjusted for multiple
 275 comparisons.

276

277 We also found some distinct quantitative differences in regional strain metrics between
 278 groups (Supplemental Tables 2 and 3). Patients with initially normal LVEF and fast
 279 progression had decreased peak systolic strain magnitude (Figure 6A) in the basal
 280 region only for E_{cc} ($p=0.002$), E_{rr} ($p=0.001$), and E_a ($p=0.003$; Figure 6B,C;

281 Supplemental Table 2) compared to those with slow progression. There were no
 282 differences in the normal cohort between fast and slow progression for systolic strain
 283 rate. However, the fast progressors had decreased early diastolic strain rate magnitude
 284 for basal E_{rr} ($p=0.001$) and global E_{rr} ($p=0.044$). There were also differences in late
 285 diastolic strain rate for E_{cc} in the basal ($p<0.001$), mid-LV ($p=0.026$), and global
 286 ($p=0.026$) regions (Figure 6F) and for E_a in the basal ($p=0.001$), mid-LV ($p=0.042$), and
 287 global ($p=0.042$) regions (Figure 6G). Between fast and slow progressors in the
 288 abnormal cohort, there were no significant differences in peak systolic strain or systolic
 289 strain rate, however, there was a difference in early diastolic strain rate for E_{ll} in the
 290 anterior segment ($p=0.048$; Supplemental Table 3). Additionally, late diastolic strain rate
 291 magnitude was decreased in fast progressors for E_{cc} in the basal ($p=0.045$) and mid-LV
 292 ($p=0.031$) regions (Figure 6H) and for E_a in the basal ($p=0.018$), mid-LV ($p=0.018$)
 293 regions, and globally ($p=0.018$; Figure 6I).



294
 295 **Figure 6:** 4D CMR regional peak strain and late diastolic strain rate can differentiate
 296 between slow and fast progression in both subclinical and clinical CMP. A) Strain curve
 297 depiction. B,C,D,E) Initial visit peak systolic strain showing differences between normal,
 298 slow progressors (initial LVEF \geq 55% +2 years Δ LVEF% \leq 5) and normal, fast progressors

299 (initial LVEF \geq 55% +2 years Δ LVEF% $>$ 5) for E_{cc} (B) and E_a (C). Peak strain differences
300 between abnormal, slow progressors (initial LVEF $<$ 55% +2 years Δ LVEF% \leq 5) and
301 abnormal, fast progressors (initial LVEF $<$ 55% +2 years Δ LVEF% $>$ 5) are shown for E_{cc}
302 (D) and E_a (E). F,G,H,I) Late diastolic strain rate differences are shown between fast
303 and slow progression in the normal cohort for E_{cc} (F) and E_a (G) and between fast and
304 slow progression in the abnormal cohort for E_{cc} (H) and E_a (I). * p $<$ 0.05 adjusted for
305 multiple comparisons.

306

307

308 **Discussion:**

309 We report here that regional 4D CMR strain parameters are useful for stratifying
310 patients based on both disease status and risk of progression. In this study, we used
311 diagnostic CMR along with regional LGE to classify and phenotype a cohort of DMD
312 patients followed annually over three visits. Further, we utilized a novel 4D CMR
313 reconstruction and feature-tracking approach to derive and assess regional strain
314 parameters. Finally, we used these strain-based parameters to evaluate differences in
315 the rate of progression between patient groups prior to changes in LVEF or LGE. These
316 findings and the metrics described here can be used to better describe the progression
317 of CMP in a cohort of DMD patients followed longitudinally over time. This information is
318 vital for improving the understanding and characteristics of this disease and justifies an
319 increased need for larger, multi-center natural history studies in this patient population.
320 It remains to be seen if 4D CMR strain parameters are modifiable or respond to
321 treatment to delay CMP progression.

322

323 *Late Gadolinium Enhancement (LGE)*

324 LGE is an important and early finding in DMD indicating the progression of CMP and
325 fibrofatty replacement of cardiac muscle. In our cohort which had a wide range of CMP
326 severity, we found that LGE presence increased over time from the initial and that the
327 presence of LGE preceded patients having an LVEF $<$ 55%, a finding similar to other
328 studies²⁰. We also found that the greatest proportion of patients developed LGE in the
329 basal and lateral portions of the left ventricle (Figure 2). At the initial visit, 25 out of the

330 26 patients with LGE had findings of LGE in the basal inferolateral region. There was
331 also the greatest increase in the proportion of patients with LGE in this region. For
332 example, there was an increase in the proportion of patients with LGE from 63% (n=25)
333 to 81% (n=29) in the basal anterolateral region throughout the study. These findings are
334 consistent with other studies that have shown regional differences in LGE presence in
335 DMD patients^{15, 21} and offer further evidence for the importance of regional assessment.

336

337 This regional variation in LGE accumulation might be partially explained by the
338 differences in stress within the left ventricle governed by the Law of Laplace. This law
339 describes how such factors as pressure, local curvature, and increased myocardial
340 thickness contribute to stress which is relatively higher in the basal segments of the
341 heart^{22, 23}. Thus, LGE accumulation in the base of the heart suggests strain parameters
342 in the basal region may be useful for differentiating disease severity and progression.

343

344 *Heart Failure Staging*

345 In previous work, we showed how 4D CMR regional strain parameters could strongly
346 differentiate between DMD and healthy control patients¹³. In this study, we
347 demonstrated that global peak strain could also differentiate between patients in Stage
348 A (LVEF \geq 55%, no LGE) and Stage B (LVEF \geq 55% with LGE; Figure 4). This is an
349 important finding because traditional metrics, such as LVEF, do not differentiate
350 between these groups. This suggests that 3D+time strain metrics may be a useful non-
351 contrast method for identifying the presence of LGE and/or fibrosis. Non-contrast
352 methods to characterize CMP onset and progression could decrease scan time, reduce
353 the need for contrast (LGE), and expand the number of DMD patients who could
354 undergo CMR¹⁵. In summary, these data suggest that 4D CMR strain might be used for
355 stratifying patient risk, increasing access to imaging, and guiding clinical management.

356

357 *Strain Mapping and Progression*

358 One of the most clinically challenging aspects of DMD CMP care is understanding the
359 risk profile of patients. By examining DMD patients with a range of CMP severity, we
360 were able to identify patients who were more likely to experience rapid progression over

361 the course of two years. We also distinguished between patient groups who initially had
362 subclinical CMP (LVEF \geq 55%) versus those who had evidence of CMP (LVEF $<$ 55%).
363 We made this initial distinction as it represents two clinically distinct groups with
364 differences in their short-term natural history that might be of interest to clinical
365 providers. Interestingly, we found that conventional metrics of LVEF, age, or LGE status
366 could not differentiate between fast or slow progression in overt or subclinical CMP. We
367 did find, however, that regional 4D CMR strain parameters could make this distinction
368 (Figure 6, Supplemental Table 2,3), suggesting this approach may be better for
369 detecting early changes in cardiac function.

370
371 The strongest differentiators for CMP progression in patients with normal function were
372 peak systolic basal E_{cc} , E_a , and E_{rr} strain, early diastolic basal E_{rr} strain rate, late
373 diastolic basal E_{cc} rate, and late diastolic basal E_a strain rate. The strongest
374 differentiators for CMP progression in patients with abnormal function were regional late
375 diastolic E_{cc} and E_a strain rates. These results indicate that, just as we observed in the
376 LGE pattern, changes in the kinematics of the basal region of the heart may be an early
377 indication of disease severity and potential for progression. These results are consistent
378 with the findings of other studies using 3D strain in DMD. Siddiqui *et al.* showed
379 previously that for DMD patients with an initial LVEF \geq 55% reductions in global 3D E_{cc}
380 and E_{rr} could be indicative of a $>$ 10% decline in LVEF up to 32 months later²⁴.

381
382 Another important finding of this study is the additive value of using regional diastolic
383 strain rate as a metric for differentiating patient progression. Others have shown that
384 abnormalities in diastolic function may be an early indication of CMP onset²⁵. To our
385 knowledge, this is the first study that describes the use of regional diastolic strain rate
386 from 4D CMR as an early metric for CMP progression in DMD. Impaired diastolic
387 relaxation in these patients may be an early sign of ventricular stiffening from fibrofatty
388 replacement of cardiomyocytes and impaired kinematics. Despite this progress, further
389 focus and study on both systolic and diastolic strain-based metrics in this population is
390 merited.

391

392 *Strengths and Limitations*

393 This study has several strengths and limitations. The analysis currently requires a post-
394 processing approach using a custom image analysis code for 4D CMR analysis.
395 Incorporation of this method or similar approach in combination with emerging artificial
396 intelligence (AI) assisted feature tracking would allow this kind of analysis to be
397 automated and performed within a reasonable clinical image analysis workflow.
398 Additionally, several of the short-axis stacks were shifted relative to others in the 3D
399 stack due to breathing and motion artifacts. This could have been partially due to the
400 young age of the patients, who may be unable to lie still during imaging for long periods
401 of time. Using contextual information from other slices, we can still evaluate these
402 images, but there was one dataset that we were unable to reconstruct in three
403 dimensions due to these artifacts. AI-assisted motion correction and CMR sequences
404 that do not rely on breath-holding could overcome these artifacts in the future. Further,
405 this is a cohort followed over three annual imaging sessions with a relatively wide range
406 of CMP severity. Though our sample size is relatively high for a rare disease, the
407 smaller sample size limits the power of our study, in particular when performing
408 subgroup analysis. Because of the limited sample size, we also did not adjust for
409 medication effects on our cohort, though all patients were treated at the same clinic with
410 standard of care and a proactive treatment approach. Therefore, the range and
411 differences in progression in our cohort are likely very similar to what a clinician would
412 be seeing in practice. Future studies with larger group sizes should adjudicate treatment
413 affects.

414
415 Strengths of this study include the longitudinal follow-up of patients, comprehensive
416 regional 4D CMR strain analysis, and the study design allowing us to evaluate the rate
417 of progression among our patients. The longitudinal analysis of patients allowed us to
418 evaluate both individual patient and group averaged progression as well as changes
419 over time. Additionally, our novel 4D CMR feature tracking software allowed us to
420 assess not only global function but also detailed spatial and temporal information for
421 each strain component. Here we also describe the use and value of surface area strain
422 (E_a) which is a parameter unique to gated 3D imaging as it is a measure of 3D surface

423 deformation. To our knowledge, this is the first description of 4D CMR strain parameters
424 for differentiation of disease severity and both subclinical and clinical rates of
425 progression.

426

427 *Conclusion*

428 In this study, we described the value of 4D CMR imaging metrics for differentiating both
429 CMP disease severity and rate of progression. We showed that basal region peak strain
430 and late diastolic strain rate for E_{cc} and E_a were correlated with the rate of cardiac
431 disease progression in DMD patients. Further studies assessing the natural history and
432 progression of DMD CMP using these techniques could help assess individual patient
433 risk profiles and guide treatment to improve clinical outcomes.

434

435 **Acknowledgments:**

436 The authors acknowledge senior imaging research specialist Kristen George-Durrett for
437 her help and expertise in image data management.

438

439 **Sources of Funding:**

440 Research reported in this publication was supported by the Ackerman/Nicholoff Family
441 (L. Markham), Fighting Duchenne Foundation and the Fight DMD/Jonah & Emory
442 Discovery Grant (J. Soslow), the Food and Drug Administration Orphan Products Grant
443 R01FD006649 (J. Soslow), the National Center for Research Resources, Grant UL1
444 RR024975-01, and is now at the National Center for Advancing Translational Sciences,
445 Grant 2 UL1 TR000445-06 (G. Bernard), and by the National Heart, Lung, and Blood
446 Institute of the National Institutes of Health under Award Number F30HL162452 (C.
447 Earl), K23HL123938 (J. Soslow), and R56HL141248 (J. Soslow). This publication was
448 also made possible with support from Grant Number, UL1TR002529 (S. Moe and S.
449 Wiehe, co-PIs) from the National Institutes of Health, National Center for Advancing


450 Translational Sciences, Clinical and Translational Sciences Award (C. Earl), and the
451 Leslie A. Geddes Endowment at Purdue University (C. Goergen). Engineering in
452 Medicine Pilot Fund between Purdue University College of Engineering and Indiana
453 University School of Medicine (L. Markham, C. Goergen, C. Earl). The content is solely
454 the responsibility of the authors and does not necessarily represent the official views of
455 the National Institutes of Health.

456

457 **Disclosures:**

458 The authors have no disclosures related to the publication of this work.

459




460 **Supplemental Tables and Figures:**

461


462 **Supplemental Figure 1:** Circumferential strain (E_{cc}) progression. A,B,C,D) E_{cc}
 463 Cartesian maps showing differences between a normal, slow progressor (A; initial
 464 LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progressor (B; initial LVEF \geq 55% +2
 465 years Δ LVEF% $>$ 5), abnormal, slow progressor (C; initial LVEF $<$ 55% +2 years
 466 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF $<$ 55%, +2 years Δ LVEF% $>$ 5)
 467 over the course of three annual visits.

468




469
 470 **Supplemental Figure 2:** Longitudinal strain (E_{II}) progression. A,B,C,D) E_{II} Cartesian
 471 maps showing differences between a normal, slow progressor (A; initial LVEF \geq 55% +2
 472 years Δ LVEF% \leq 5), normal, fast progressor (B; initial LVEF \geq 55% +2 years Δ LVEF% $>$ 5),
 473 abnormal, slow progressor (C; initial LVEF $<$ 55% +2 years Δ LVEF% \leq 5), abnormal, fast
 474 progressor (D; initial LVEF $<$ 55%, +2 years Δ LVEF% $>$ 5) over the course of three annual
 475 visits.

476
 477
 478
 479
 480



481
 482 **Supplemental Figure 3:** Radial strain (E_{rr}) progression. A,B,C,D) E_{rr} polar strain maps
 483 at peak systole showing differences between a normal, slow progressor (A; initial
 484 LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progressor (B; initial LVEF \geq 55% +2
 485 years Δ LVEF% $>$ 5), abnormal, slow progressor (C; initial LVEF $<$ 55% +2 years
 486 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF $<$ 55%, +2 years Δ LVEF% $>$ 5)
 487 over the course of three annual visits.

488
 489
 490
 491



492

493 **Supplemental Figure 4:** Surface area strain (E_a) progression. A,B,C,D) E_a polar strain
 494 maps at peak systole showing differences between a normal, slow progressor (A; initial
 495 LVEF \geq 55% +2 years Δ LVEF% \leq 5), normal, fast progressor (B; initial LVEF \geq 55% +2
 496 years Δ LVEF% $>$ 5), abnormal, slow progressor (C; initial LVEF $<$ 55% +2 years
 497 Δ LVEF% \leq 5), abnormal, fast progressor (D; initial LVEF $<$ 55%, +2 years Δ LVEF% $>$ 5)
 498 over the course of three annual visits.

499

500

501

502

503 **Supplemental Table 1: Regional 4D CMR peak systolic strain differences between**
 504 heart failure stages.

Strain	Region	Peak Strain				p value					
		Stage A	Stage B	Stage C	Stage D	A-B	A-C	A-D	B-C	B-D	C-D
Circumferential E _{cc}	Base	-20±1.3	-18.3±2.9	-16.1±2.1	-10±3.9	0.292	0.003*	0.000*	0.145	0.000*	0.002*
	Mid	-22.2±2.8	-20.1±3.8	-18.2±2.4	-11.6±5.7	0.390	0.044*	0.000*	0.568	0.002*	0.025*
	Apex	-27.4±5.9	-23.8±7.2	-20.2±3.2	-12±4.3	0.417	0.037*	0.001*	0.495	0.017*	0.175
	Global	-23.2±3	-20.7±4	-18.2±1.7	-11.1±4.5	0.214	0.006*	0.000*	0.315	0.000*	0.013*
Longitudinal E _{ll}	Anterior FW	-23.2±3	-20.7±4	-18.2±1.7	-11.1±4.5	0.214	0.006*	0.000*	0.315	0.000*	0.013*
	Anterior	-11.2±2.1	-9.3±2.3	-9.4±1.2	-5.7±2.2	0.088	0.209	0.001*	0.997	0.045*	0.042*
	Anterior S	-9.9±1.7	-7.6±1.4	-7.6±1.8	-6.2±1.1	0.003*	0.011*	0.004*	0.999	0.519	0.504
	Posterior S	-9.8±1.8	-7.7±1.3	-7.9±1.7	-6.7±1.2	0.009*	0.032*	0.017*	0.997	0.718	0.662
	Posterior	-11.2±1.9	-8.6±1.6	-8.6±1.6	-6.5±2.6	0.005*	0.011*	0.001*	0.999	0.253	0.284
	Posterior FW	-11.5±1.2	-9.3±1.5	-8.5±1.3	-6.1±2.8	0.003*	0.000*	0.000*	0.577	0.007*	0.075
	Global	-10.9±1.5	-8.6±1.4	-8.6±1.2	-6.1±1.8	0.002*	0.003*	0.000*	0.999	0.042*	0.065
Radial E _{rr}	Base	27.6±10.1	24.8±10.7	18.1±10.5	7.2±4.1	0.897	0.151	0.018*	0.424	0.049*	0.393
	Mid	29.9±11.4	17.2±7.8	21.3±10.8	8.3±10.7	0.015*	0.216	0.010*	0.793	0.518	0.235
	Apex	21.9±12.7	9.6±4.2	13.2±7.9	5.7±5.7	0.007*	0.133	0.036*	0.783	0.901	0.586
	Global	27±9.5	18.2±6.3	18.1±8.3	7.2±6.9	0.038*	0.065	0.003*	0.999	0.165	0.200
Surface Area E _a	Base	-27.9±1.8	-25.2±2.8	-22.4±1.8	-14.6±4.4	0.033*	0.000*	0.000*	0.057	0.000*	0.000*
	Mid	-30.7±3.6	-27.1±4	-24.2±2.4	-16.2±6.5	0.082	0.002*	0.000*	0.304	0.000*	0.014*
	Apex	-39.5±7.4	-33.7±8.3	-29.4±5	-18.7±6	0.180	0.014*	0.000*	0.539	0.014*	0.137
	Global	-31.9±3.4	-28±3.9	-24.9±1.9	-16.2±5.5	0.037*	0.000*	0.000*	0.172	0.000*	0.004*

505 *Stage A (LVEF≥55%, no LGE); Stage B (LVEF≥55%, with LGE); Stage C (40%<LVEF<55%, with*
 506 *LGE); Stage D (LVEF<40%, with LGE); *p<0.05, adjusted for multiple comparisons.*
 507

508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519

520 **Supplemental Table 2: Regional strain differences between cardiomyopathy groups**
 521 with normal LVEF:

Strain	Region	Peak			Systolic Strain Rate			Early Diastolic Strain Rate			Late Diastolic Strain Rate		
		Group 1	Group 2	p	Group 1	Group 2	p	Group 1	Group 2	p	Group 1	Group 2	p
Circumferential E _{cc}	Base	-20.5±1.8	-17.5±2.1	0.002*	-1.19±0.3	-1.04±0.1	0.348	1.05±0.3	0.85±0.2	0.193	1.08±0.2	0.71±0.2	0.000*
	Mid	-21.3±3.4	-20.4±3.2	0.745	-1.36±0.5	-1.24±0.2	0.365	1.16±0.4	0.99±0.2	0.23	1.11±0.3	0.84±0.2	0.026*
	Apex	-25.9±6.9	-25±6.4	0.745	-1.78±0.6	-1.54±0.4	0.364	1.57±0.6	1.32±0.4	0.23	1.35±0.6	1.03±0.4	0.134
	Global	-22.5±3.8	-21±3.3	0.629	-1.51±0.3	-1.25±0.2	0.075	1.25±0.4	1.03±0.2	0.208	1.14±0.3	0.87±0.2	0.026*
Longitudinal E _{ll}	Anterior FW	-10.2±1.8	-10.9±2	0.956	-0.57±0.1	-0.62±0.1	0.836	0.48±0.1	0.5±0.1	0.997	0.46±0.1	0.4±0.1	0.775
	Anterior	-9.7±2.7	-10.7±2.2	0.929	-0.56±0.2	-0.61±0.1	0.945	0.45±0.1	0.45±0.1	0.999	0.4±0.1	0.42±0.1	0.976
	Anterior S	-8.4±2.1	-8.9±1.8	0.979	-0.47±0.1	-0.5±0.1	0.945	0.36±0.1	0.37±0.1	0.999	0.37±0.1	0.35±0.1	0.976
	Posterior S	-8.5±1.8	-8.8±1.9	0.979	-0.48±0.1	-0.51±0.1	0.945	0.37±0.1	0.36±0.1	0.999	0.37±0.1	0.34±0.1	0.976
	Posterior	-9.7±2.1	-9.9±2.2	0.979	-0.53±0.1	-0.58±0.2	0.945	0.45±0.1	0.42±0.1	0.959	0.39±0.1	0.38±0.1	0.976
	Posterior FW	-10.3±1.8	-10.3±1.6	0.979	-0.58±0.1	-0.58±0.1	0.945	0.5±0.1	0.48±0.1	0.999	0.46±0.1	0.38±0.1	0.309
	Global	-9.5±1.9	-9.9±1.7	0.979	-0.53±0.1	-0.57±0.1	0.945	0.43±0.1	0.42±0.1	0.999	0.41±0.1	0.37±0.1	0.929
Radial E _{rr}	Base	34.6±10.2	20.2±6.9	0.001*	1.77±0.9	1.03±0.5	0.054	-2.65±0.7	-1.5±0.7	0.001*	-1.29±1.1	-0.63±0.5	0.204
	Mid	23.2±7.5	22.3±15	0.979	1.02±0.4	1.38±1.2	0.695	-1.96±0.6	-1.48±1	0.256	-0.58±0.8	-0.93±0.9	0.672
	Apex	15.6±9.2	15±12.7	0.979	0.75±0.8	0.86±0.8	0.88	-1.31±0.8	-1.12±1	0.596	-0.5±0.8	-0.58±1.1	0.935
	Global	25.5±6.6	19.7±10.5	0.286	1.23±0.5	1.12±0.7	0.88	-2.06±0.4	-1.4±0.8	0.044*	-0.82±0.8	-0.73±0.7	0.935
Surface Area E _a	Base	-28±1.8	-24.7±2.4	0.003*	-1.63±0.2	-1.46±0.2	0.117	1.39±0.2	1.19±0.2	0.131	1.35±0.3	0.99±0.2	0.001*
	Mid	-29.2±4.1	-27.6±3.8	0.509	-1.84±0.3	-1.66±0.2	0.199	1.47±0.4	1.29±0.2	0.222	1.4±0.3	1.11±0.2	0.042*
	Apex	-36.6±8.6	-35.8±7.7	0.802	-2.46±0.7	-2.21±0.4	0.299	2.16±0.8	1.8±0.4	0.222	1.75±0.6	1.58±0.5	0.431
	Global	-30.6±4.1	-28.6±3.5	0.452	-1.92±0.3	-1.72±0.2	0.199	1.61±0.4	1.38±0.2	0.152	1.47±0.3	1.18±0.2	0.042*

522 *Group 1: normal, slow progression (initial LVEF≥55%, +2 years ΔLVEF%≤5) and Group 2: normal, fast*
 523 *progression (initial LVEF≥55%, +2 years ΔLVEF%≤5); *p<0.05, adjusted for multiple comparisons.*
 524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541 **Supplemental Table 3: Regional strain differences between DMD cardiomyopathy**

542 groups with abnormal LVEF

Strain	Region	Peak			Systolic Strain Rate			Early Diastolic Strain Rate			Late Diastolic Strain Rate		
		Group 3	Group 4	p	Group 3	Group 4	p	Group 3	Group 4	p	Group 3	Group 4	p
Circumferential E_{cc}	Base	-15.9±2.4	-11.8±4.6	0.185	-0.88±0.2	-0.78±0.4	0.547	0.88±0.2	0.57±0.2	0.096	0.68±0.2	0.4±0.2	0.045*
	Mid	-18.3±2.4	-13±5.6	0.145	-1.06±0.2	-0.73±0.3	0.148	0.97±0.3	0.7±0.3	0.258	0.79±0.2	0.48±0.1	0.031*
	Apex	-19.4±3.4	-15.6±7.1	0.233	-1.16±0.3	-0.88±0.4	0.385	1.15±0.4	0.73±0.4	0.258	0.83±0.3	0.6±0.3	0.188
	Global	-17.9±1.9	-13.5±5.7	0.185	-1.03±0.2	-0.79±0.3	0.334	1±0.2	0.66±0.3	0.148	0.75±0.2	0.48±0.2	0.053
Longitudinal E_{ll}	Anterior FW	-9.1±1.9	-7.8±3.4	0.951	-0.49±0.1	-0.41±0.2	0.942	0.44±0.2	0.34±0.1	0.867	0.36±0.1	0.28±0.1	0.489
	Anterior	-9.2±1.3	-7.1±3.1	0.57	-0.48±0.1	-0.4±0.2	0.919	0.45±0.1	0.29±0.1	0.048*	0.35±0.1	0.27±0.1	0.489
	Anterior S	-7.2±1.6	-7.5±2.1	0.97	-0.39±0.1	-0.42±0.1	0.991	0.34±0.1	0.34±0.1	0.997	0.28±0.1	0.28±0.1	0.957
	Posterior S	-7.6±1.5	-7.4±2	0.97	-0.42±0.1	-0.43±0.1	0.991	0.35±0.1	0.38±0.1	0.984	0.31±0.1	0.27±0.1	0.629
	Posterior	-8.3±1.8	-7.6±2.7	0.97	-0.45±0.1	-0.43±0.2	0.991	0.38±0.1	0.35±0.1	0.984	0.34±0.1	0.24±0.1	0.452
	Posterior FW	-8.1±1.5	-7.6±2.9	0.97	-0.42±0.1	-0.4±0.2	0.991	0.36±0.1	0.33±0.1	0.984	0.34±0.1	0.26±0.1	0.452
	Global	-8.2±1.2	-7.4±2.6	0.961	-0.44±0.1	-0.4±0.1	0.99	0.38±0.1	0.33±0.1	0.897	0.32±0	0.24±0.1	0.397
Radial E_{rr}	Base	14.9±9.7	16.2±13.1	0.999	0.59±0.7	2.06±1.4	0.129	-1.18±1	-1.78±1.4	0.873	-0.5±0.7	-0.49±0.4	0.967
	Mid	18.6±9.7	16.8±17	0.999	0.78±0.7	1.39±1.2	0.491	-1.51±0.7	-1.91±1.2	0.873	-0.41±0.7	-0.7±1	0.958
	Apex	11.5±7.4	10.9±10.1	0.999	0.47±0.5	0.62±0.6	0.66	-0.94±0.6	-0.95±0.7	0.971	-0.19±0.5	-0.4±0.6	0.958
	Global	15.5±7	15.1±13.7	0.999	0.63±0.6	1.45±1	0.261	-1.24±0.6	-1.62±1.1	0.873	-0.39±0.6	-0.55±0.7	0.958
Surface Area E_a	Base	-22.1±2.4	-17.3±5.8	0.238	-1.17±0.1	-1.13±0.5	0.843	1.19±0.2	0.88±0.2	0.076	0.93±0.1	0.63±0.1	0.018*
	Mid	-23.9±2.7	-18.8±7.2	0.25	-1.34±0.1	-1.09±0.5	0.605	1.29±0.2	0.98±0.2	0.088	0.98±0.2	0.61±0.2	0.018*
	Apex	-28.2±5.2	-23.8±9.8	0.323	-1.62±0.3	-1.42±0.5	0.753	1.64±0.5	1.28±0.5	0.272	1.25±0.3	0.9±0.2	0.082
	Global	-24.3±2.3	-19.5±7.3	0.25	-1.35±0.1	-1.19±0.5	0.753	1.34±0.2	1.02±0.3	0.088	1.03±0.2	0.69±0.1	0.018*

543 *Group 3: abnormal, slow progression (C; initial LVEF<55%, +2 years Δ LVEF% \leq 5); Group 4:*
 544 *abnormal, fast progression (D; initial LVEF<55%, +2 years Δ LVEF%>5); *p<0.05, adjusted for*
 545 *multiple comparisons.*

546

547

548

549 **References:**

550

- 551 1. Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J and Lochmüller H. Life
552 expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis.
553 *European Journal of Epidemiology*. 2020;35:643-653.
- 554 2. Crisafulli S, Sultana J, Fontana A, Salvo F, Messina S and Trifirò G. Global
555 epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-
556 analysis. *Orphanet Journal of Rare Diseases*. 2020;15.
- 557 3. Ryder S, Leadley RM, Armstrong N, Westwood M, De Kock S, Butt T, Jain M and
558 Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an
559 evidence review. *Orphanet Journal of Rare Diseases*. 2017;12.
- 560 4. Meyers TA and Townsend D. Cardiac Pathophysiology and the Future of Cardiac
561 Therapies in Duchenne Muscular Dystrophy. *International Journal of Molecular Sciences*.
562 2019;20:4098.
- 563 5. Shih JA, Folch A and Wong BL. Duchenne Muscular Dystrophy: the Heart of the Matter.
564 *Current Heart Failure Reports*. 2020;17:57-66.
- 565 6. Angulski ABB, Hosny N, Cohen H, Martin AA, Hahn D, Bauer J and Metzger JM.
566 Duchenne muscular dystrophy: disease mechanism and therapeutic strategies. *Frontiers in*
567 *Physiology*. 2023;14.
- 568 7. Lee S, Lee M and Hor KN. The role of imaging in characterizing the cardiac natural
569 history of Duchenne muscular dystrophy. *Pediatric Pulmonology*. 2021;56:766-781.
- 570 8. Earl CC, Soslow JH, Markham LW and Goergen CJ. Myocardial strain imaging in
571 Duchenne muscular dystrophy. *Frontiers in Cardiovascular Medicine*. 2022;9.
- 572 9. Blaszczyk E, Gröschel J and Schulz-Menger J. Role of CMR Imaging in Diagnostics and
573 Evaluation of Cardiac Involvement in Muscle Dystrophies. *Current Heart Failure Reports*.
574 2021;18:211-224.
- 575 10. Prakash N, Suthar R, Sihag BK, Debi U, Kumar RM and Sankhyan N. Cardiac MRI and
576 echocardiography for early diagnosis of cardiomyopathy among boys with Duchenne muscular
577 dystrophy: a cross-sectional study. *Frontiers in Pediatrics*. 2022;10:818608.
- 578 11. Lechner A, Herzig JJ, Kientsch JG, Kohler M, Bloch KE, Ulrich S and Schwarz EI.
579 Cardiomyopathy as cause of death in Duchenne muscular dystrophy: a longitudinal observational
580 study. *ERJ Open Research*. 2023;9:00176-2023.
- 581 12. Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, Pack N, Dibella E
582 and Gottliebson WM. Late gadolinium enhancement: precursor to cardiomyopathy in Duchenne
583 muscular dystrophy? *The International Journal of Cardiovascular Imaging*. 2009;25:57-63.
- 584 13. Earl CC, Pyle VI, Clark SQ, Annamalai K, Torres PA, Quintero A, Damen FW, Hor KN,
585 Markham LW, Soslow JH and Goergen CJ. Localized strain characterization of cardiomyopathy
586 in Duchenne muscular dystrophy using novel 4D kinematic analysis of cine cardiovascular
587 magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*. 2023;25.
- 588 14. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A,
589 Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez
590 AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nwacheta LC, Sandhu AT,
591 Stevenson LW, Vardeny O, Vest AR and Yancy CW. 2022 AHA/ACC/HFSA Guideline for the
592 Management of Heart Failure: A Report of the American College of Cardiology/American Heart
593 Association Joint Committee on Clinical Practice Guidelines. *Circulation*. 2022;145.

- 594 15. Raucci FJ, Xu M, George-Durrett K, Crum K, Slaughter JC, Parra DA, Markham LW
595 and Soslow JH. Non-contrast cardiovascular magnetic resonance detection of myocardial fibrosis
596 in Duchenne muscular dystrophy. *Journal of Cardiovascular Magnetic Resonance*. 2021;23.
- 597 16. Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, Pennell DJ,
598 Rumberger JA, Ryan T and Verani MS. Standardized Myocardial Segmentation and
599 Nomenclature for Tomographic Imaging of the Heart. *Circulation*. 2002;105:539-542.
- 600 17. Dann MM, Clark SQ, Trzaskalski NA, Earl CC, Schepers LE, Pulente SM, Lennord EN,
601 Annamalai K, Gruber JM and Cox A. Quantification of Murine Myocardial Infarct Size using 2D
602 and 4D High Frequency Ultrasound. *American Journal of Physiology-Heart and Circulatory*
603 *Physiology*. 2022.
- 604 18. Damen FW, Salvas JP, Pereyra AS, Ellis JM and Goergen CJ. Improving characterization
605 of hypertrophy-induced murine cardiac dysfunction using four-dimensional ultrasound derived
606 strain mapping. *American Journal of Physiology-Heart and Circulatory Physiology*. 2021.
- 607 19. Leyba K, Paiyabhroma N, Salvas JP, Damen FW, Janvier A, Zub E, Bernis C, Rouland
608 R, Dubois CJ, Badaut J, Richard S, Marchi N, Goergen CJ and Sicard P. Neurovascular hypoxia
609 after mild traumatic brain injury in juvenile mice correlates with heart–brain dysfunctions in
610 adulthood. *Acta Physiologica*. 2023;238.
- 611 20. Hor KN, Kissoon N, Mazur W, Gupta R, Ittenbach RF, Al-Khalidi HR, Cripe LH, Raman
612 SV, Puchalski MD, Gottliebson WM and Benson DW. Regional Circumferential Strain is a
613 Biomarker for Disease Severity in Duchenne Muscular Dystrophy Heart Disease: A Cross-
614 Sectional Study. *Pediatric Cardiology*. 2015;36:111-119.
- 615 21. Kerstens TP, van Everdingen WM, Habets J, van Dijk AP, Helbing WA, Thijssen DH
616 and Ten Cate FEU. Left ventricular deformation and myocardial fibrosis in pediatric patients
617 with Duchenne muscular dystrophy. *International Journal of Cardiology*. 2023;388:131162.
- 618 22. Skaarup KG, Lassen MCH, Marott JL, Biering-Sørensen SR, Jørgensen PG, Appleyard
619 M, Berning J, Høst N, Jensen G, Schnohr P, Søggaard P, Gislason G, Møgelvang R and Biering-
620 Sørensen T. The impact of cardiovascular risk factors on global longitudinal strain over a decade
621 in the general population: the copenhagen city heart study. *The International Journal of*
622 *Cardiovascular Imaging*. 2020;36:1907-1916.
- 623 23. Grossman W, Jones D and McLaurin LP. Wall stress and patterns of hypertrophy in the
624 human left ventricle. *Journal of Clinical Investigation*. 1975;56:56-64.
- 625 24. Siddiqui S, Alsaied T, Henson SE, Gandhi J, Patel P, Khoury P, Villa C, Ryan TD,
626 Wittekind SG, Lang SM and Taylor MD. Left Ventricular Magnetic Resonance Imaging Strain
627 Predicts the Onset of Duchenne Muscular Dystrophy–Associated Cardiomyopathy. *Circulation:*
628 *Cardiovascular Imaging*. 2020;13.
- 629 25. Markham LW, Michelfelder EC, Border WL, Khoury PR, Spicer RL, Wong BL, Benson
630 DW and Cripe LH. Abnormalities of Diastolic Function Precede Dilated Cardiomyopathy
631 Associated with Duchenne Muscular Dystrophy. *Journal of the American Society of*
632 *Echocardiography*. 2006;19:865-871.
- 633

Figure 1:

A DMD-Associated Cardiomyopathy Staging

Stage A: At risk for HF	LVEF \geq 55%, LGE (-)
Stage B: Pre-HF	LVEF $>$ 55%, LGE(+)
Stage C: Symptomatic HF	40% $<$ LVEF $<$ 55%, LGE(+/-)
Stage D: Advanced HF	LVEF $<$ 40%, LGE(+)





Table 1:

	Visit 1	Visit 2	Visit 3
	(n=40)	(n=38)	(n=36)
Age (years)	12.4 [10.5-16.6]	12.8 [11.5-17.0]	13.7 [12.5-17.0]
Height (cm)	146 [127-163]	152 [142-161]	152 [142-163]
Weight (kg)	47.2 [36.4-65.0]	53.6 [39.5-69.9]	58.5 [43.2-72.8]
BSA (m²)	1.4 [1.2-1.7]	1.5 [1.3-1.8]	1.6 [1.3-1.8]
HR (BPM)	103 [92-116]	97 [89-105]	100 [89-111]
Systolic (mmHg)	115 [107-120]	117 [106-123]	115 [105-120]
Diastolic (mmHg)	66 [61-74]	68 [63-74]	69 [59-76]
LVEF (%)	59 [51-62]	57 [49-59]	55 [49-58]
LVEDVI (ml/m²)	59 [54-70]	61 [52-68]	65 [57-71]
LVESVI (ml/m²)	24 [20-34]	26 [22-33]	29 [25-34]
CO (L/min)	4.9 [4.0-5.8]	4.7 [4.1-5.3]	5.1 [4.0-6.0]
LVEF<55%, n(%)	12 (30)	16 (42)	18 (50)
+LGE, n(%)	26 (65)	29 (76)	34 (94)
Stage A, n(%)	14 (35)	9 (24)	2 (6)
Stage B, n(%)	14 (35)	13 (34)	16 (44)
Stage C, n(%)	9 (22.5)	14 (37)	16 (44)
Stage D, n(%)	3 (7.5)	2 (5)	2 (6)

BSA, body surface area; HR, heart rate; LVEF, left ventricular ejection fraction; LVEDVI, left ventricular end diastolic volume indexed to BSA; LVESVI, left ventricular end systolic volume indexed to BSA; LVCO, left ventricular cardiac output; LGE, late gadolinium enhancement.

Stage A, LVEF>55%, LGE(-); Stage B, LVEF>55%, LGE(+); Stage C, 40%<LVEF<55%, LGE(+); Stage D, LVEF<40%, LGE(+). Values reported as median [interquartile range] or as number of subjects (percentage of group)—n(%).

Figure 2:




Figure 3:





Figure 5:

A Initial Visit


+2 years Progression

Initial Visit Group-Averaged Strain




D


Normal
Slow
↓
Apex




FW
Ant.
Sept.
Post.
FW



FW
Ant.
Sept.
Post.
FW




SEPTAL
FREE-WALL




SEPTAL
FREE-WALL

E


Normal
Fast
↓
Apex




FW
Ant.
Sept.
Post.
FW



FW
Ant.
Sept.
Post.
FW




SEPTAL
FREE-WALL




SEPTAL
FREE-WALL

F


Abnormal
Slow
↓
Apex




FW
Ant.
Sept.
Post.
FW



FW
Ant.
Sept.
Post.
FW




SEPTAL
FREE-WALL




SEPTAL
FREE-WALL

G


Abnormal
Fast
↓
Apex




FW
Ant.
Sept.
Post.
FW




FW
Ant.
Sept.
Post.
FW




SEPTAL
FREE-WALL



SEPTAL
FREE-WALL



B



C






Figure 6:



Initial Visit Peak Strain

Initial Visit Late Diastolic Strain Rate

